BCL2L1 and renal cell carcinoma: Treatment with DT2216 led to a significant decrease in BCL-XL levels within TI-Tregs from human BrCa (Fig. 2a, b and Supplementary Fig. 4b, c) and RCC (Fig. 2c, d and Supplementary Fig. 4d).